CTT on Renogram as an Early Marker of Significant Obstruction in Uretero-pelvic Junction Syndrome

Condition(s) studied

Investigational drug(s) / intervention(s)

ultrasonography: bilateral ultrasonography to measure the antero-posterior renal pelvic diameter (APRPD) in both positions.

diuretic renography: diuretic renography to measure the cortical transit time.

Study summary

Cortical transit time on diuretic renogram as an early marker of significant obstruction in antenatally detected uretero-pelvic junction syndrome

Eligibility

Primary outcome measure(s)

• risk, during the first year of life, of an increase of 4mm or more in the measure of APRPD by ultrasonography as compared to the baseline measure, according to the presence or not of an abnormal cortical transit ti — 3 months, 6 months and 12 months
  During the first year of life, the antero-posterior renal pelvic diameter will be measured by ultrasonography at baseline, then at 3 months, 6 months and 12 months after baseline. Diuretic renography will be performed only at baseline and the cortical transit time will be classified as normal or abnormal. An increase of 4mm or more of APRPD is the threshold chosen in the study to determine the aggravation of hydronephrosis. The occurence of the increase of 4mm or more in the measure of APRPD will be compared with the normality/abnormality of the cortical transit time in order to determine its value as a prognostic marker.

Trial sites (5)

More Centre Hospitalier Universitaire de la Réunion trials in France